Skip to main content
Top
Published in: Annals of General Psychiatry 1/2007

Open Access 01-12-2007 | Primary research

QTc and psychopharmacs: are there any differences between monotherapy and polytherapy

Authors: Jadranka Čulav Sumić, Vesna Barić, Petar Bilić, Miroslav Herceg, Mirna Sisek-Šprem, Vlado Jukić

Published in: Annals of General Psychiatry | Issue 1/2007

Login to get access

Abstract

Background

Some psychotropic drugs are connected with prolongation of QT interval, increased risk of cardiac arrhythmias and greater incidence of sudden death, especially when used in combination. Concomitant use of antipsychotics and antidepressants is not rare in our clinical practice. The study compares the length of QT interval in patients on monotherapy with an antipsychotic or an antidepressant and patients taking polytherapy (an antipsychotic agent combined with an antidepressant).

Methods

Sixty-one hospitalized women who met the ICD-10 criteria for schizophrenia, schizoaffective psychosis, delusional disorder and mood disorder were included in the study. The monotherapy group was consisted of thirty-two women treated with an antipsychotic or an antidepressant while the polytherapy group was composed of twenty-nine women treated with an antipsychotic agent plus an antidepressant. Two electrocardiograms (ECGs) were obtained for each patient: the first was carried out before the treatment and the second after two weeks of treatment.
Statistical analysis was carried out by SPSS program and included unpaired and paired t test and Fisher's exact test.

Results

Mean baseline QTc values did not differ between the groups (439 ± 22 ms was the same value found in the both groups; unpaired t test, p > 0.5). Mean QTc intervals after two weeks of treatment were also similar (439 ± 24 ms in the monotherapy group and 440 ± 20 ms in the polytherapy group; unpaired t test, p > 0.5). Fisher's exact test did not reveal significant difference in the number of patients with borderline (451–470 ms) or prolonged (> 470 ms) QTc between groups, neither before treatment nor after two weeks of treatment. Twenty two women of the total of sixty one patients (36%) had QTc > 450 ms before applying therapy.

Conclusion

We did not find significant QT prolongation in our patients after two weeks of treatment with antipsychotics and/or antidepressants. The QTc interval length did not differ significantly in the monotherapy and the polytherapy group. More than one third of included women exceeded the threshold value of borderline QTc interval (450 ms) before starting treatment. This finding calls for caution when prescribing drugs to female psychiatric patients, especially if they have other health problems.
Literature
1.
go back to reference Straus SMJM, Sturkenboom MCJM, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, Kingma JH, Stricker BHCh: Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. European HeartJournal. 2005, 26: 2007-2012. 10.1093/eurheartj/ehi312.CrossRef Straus SMJM, Sturkenboom MCJM, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, Kingma JH, Stricker BHCh: Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. European HeartJournal. 2005, 26: 2007-2012. 10.1093/eurheartj/ehi312.CrossRef
2.
go back to reference Straus SMJM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GE, Kingma JH, Sturkenboom MCJM, Stricker BHCh: Antipsychotic and the risk of sudden cardiac death. Arch Intern Med. 2004, 164: 1293-1297. 10.1001/archinte.164.12.1293.CrossRefPubMed Straus SMJM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GE, Kingma JH, Sturkenboom MCJM, Stricker BHCh: Antipsychotic and the risk of sudden cardiac death. Arch Intern Med. 2004, 164: 1293-1297. 10.1001/archinte.164.12.1293.CrossRefPubMed
4.
go back to reference Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, Glasser DB, Morrison MF, Strom BL: Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002, 325: 1070-1074. 10.1136/bmj.325.7372.1070.PubMedCentralCrossRefPubMed Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, Glasser DB, Morrison MF, Strom BL: Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002, 325: 1070-1074. 10.1136/bmj.325.7372.1070.PubMedCentralCrossRefPubMed
5.
go back to reference Fayek M, Kingsbury SJ, Zada J, Simpson GM: Cardiac effects of antipsychotic medications. Psychiatr Serv. 2001, 52: 607-609. 10.1176/appi.ps.52.5.607.CrossRefPubMed Fayek M, Kingsbury SJ, Zada J, Simpson GM: Cardiac effects of antipsychotic medications. Psychiatr Serv. 2001, 52: 607-609. 10.1176/appi.ps.52.5.607.CrossRefPubMed
6.
go back to reference Vieweg WVR, Wood MA: Tricyclic antidepressants, QT interval prolongation and torsade de pointes. Psychosomatics. 2004, 45: 371-377. 10.1176/appi.psy.45.5.371.CrossRefPubMed Vieweg WVR, Wood MA: Tricyclic antidepressants, QT interval prolongation and torsade de pointes. Psychosomatics. 2004, 45: 371-377. 10.1176/appi.psy.45.5.371.CrossRefPubMed
7.
go back to reference Glassman AH, Bigger JT: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001, 158: 1774-1782. 10.1176/appi.ajp.158.11.1774.CrossRefPubMed Glassman AH, Bigger JT: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001, 158: 1774-1782. 10.1176/appi.ajp.158.11.1774.CrossRefPubMed
8.
go back to reference Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MV, Laks MM, Macfarlane PV, Sommargren C, Swiryn S, Van Hare GF: Practice standards for electrocardiographic monitoring in hospital settings. Circulation. 2004, 110: 2721-2746. 10.1161/01.CIR.0000145144.56673.59.CrossRefPubMed Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MV, Laks MM, Macfarlane PV, Sommargren C, Swiryn S, Van Hare GF: Practice standards for electrocardiographic monitoring in hospital settings. Circulation. 2004, 110: 2721-2746. 10.1161/01.CIR.0000145144.56673.59.CrossRefPubMed
10.
go back to reference Cheng J: Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human. Fundam Clin Pharmacol. 2006, 20: 1-8. 10.1111/j.1472-8206.2005.00384.x.CrossRefPubMed Cheng J: Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human. Fundam Clin Pharmacol. 2006, 20: 1-8. 10.1111/j.1472-8206.2005.00384.x.CrossRefPubMed
11.
go back to reference Pham TV, Rosen MR: Sex, hormones, and repolarization. Cardiovasc Res. 2002, 53: 740-751. 10.1016/S0008-6363(01)00429-1.CrossRefPubMed Pham TV, Rosen MR: Sex, hormones, and repolarization. Cardiovasc Res. 2002, 53: 740-751. 10.1016/S0008-6363(01)00429-1.CrossRefPubMed
12.
go back to reference Drici M-D: Influence of gender on drug-acquired long QT syndrome. Eur Heart J Supplements. 2001, 3 (Suppl K): K41-K47. 10.1016/S1520-765X(01)90005-7.CrossRef Drici M-D: Influence of gender on drug-acquired long QT syndrome. Eur Heart J Supplements. 2001, 3 (Suppl K): K41-K47. 10.1016/S1520-765X(01)90005-7.CrossRef
13.
go back to reference Ito H, Kono T, Ishida S, Maeda H: Gender difference in QTc prolongation of people with mental disorders. Ann Gen Hosp Psychiatry. 2004, 3: 3-10.1186/1475-2832-3-3.PubMedCentralCrossRefPubMed Ito H, Kono T, Ishida S, Maeda H: Gender difference in QTc prolongation of people with mental disorders. Ann Gen Hosp Psychiatry. 2004, 3: 3-10.1186/1475-2832-3-3.PubMedCentralCrossRefPubMed
14.
go back to reference Van Mieghem C, Sabbe M, Knockaert D: The clinical value of the ECG in noncardiac conditions. CHEST. 2004, 125: 1561-1576. 10.1378/chest.125.4.1561.CrossRefPubMed Van Mieghem C, Sabbe M, Knockaert D: The clinical value of the ECG in noncardiac conditions. CHEST. 2004, 125: 1561-1576. 10.1378/chest.125.4.1561.CrossRefPubMed
15.
go back to reference Llerena A, Berecz R, Dorado P, De la Rubia A: QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol. 2004, 18: 189-193. 10.1177/0269881104042618.CrossRefPubMed Llerena A, Berecz R, Dorado P, De la Rubia A: QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol. 2004, 18: 189-193. 10.1177/0269881104042618.CrossRefPubMed
16.
go back to reference O'Brien P, Oyebode F: Psychotropic medication and the heart. Adv Psychiatr Treat. 2003, 9: 414-423. 10.1192/apt.9.6.414.CrossRef O'Brien P, Oyebode F: Psychotropic medication and the heart. Adv Psychiatr Treat. 2003, 9: 414-423. 10.1192/apt.9.6.414.CrossRef
18.
go back to reference Kass RS, Moss AJ: Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J Clin Invest. 2003, 112: 810-815. 10.1172/JCI200319844.PubMedCentralCrossRefPubMed Kass RS, Moss AJ: Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J Clin Invest. 2003, 112: 810-815. 10.1172/JCI200319844.PubMedCentralCrossRefPubMed
20.
go back to reference Clancy cE, Kass RS: Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels. Physiol Rev. 2005, 85: 33-47. 10.1152/physrev.00005.2004.CrossRefPubMed Clancy cE, Kass RS: Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels. Physiol Rev. 2005, 85: 33-47. 10.1152/physrev.00005.2004.CrossRefPubMed
21.
go back to reference Priori SG: Inherited Arrhythmogenic Disease: The complexity beyond monogenic disorders (reviews). Circ Res. 2004, 94: 140-145. 10.1161/01.RES.0000115750.12807.7E.CrossRefPubMed Priori SG: Inherited Arrhythmogenic Disease: The complexity beyond monogenic disorders (reviews). Circ Res. 2004, 94: 140-145. 10.1161/01.RES.0000115750.12807.7E.CrossRefPubMed
23.
go back to reference Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL, Roden DM: Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002, 105: 1943-1948. 10.1161/01.CIR.0000014448.19052.4C.CrossRefPubMed Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL, Roden DM: Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002, 105: 1943-1948. 10.1161/01.CIR.0000014448.19052.4C.CrossRefPubMed
24.
go back to reference Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC: A structural basis for drug-induced long QT syndrome. PNAS. 2000, 97: 12329-12333. 10.1073/pnas.210244497.PubMedCentralCrossRefPubMed Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC: A structural basis for drug-induced long QT syndrome. PNAS. 2000, 97: 12329-12333. 10.1073/pnas.210244497.PubMedCentralCrossRefPubMed
26.
go back to reference Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JRS, Caverzasi E, Bonzano A, Piccinelli M, Barale F, de Ferrari GM: QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005, 4: 1-10.1186/1744-859X-4-1.PubMedCentralCrossRefPubMed Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JRS, Caverzasi E, Bonzano A, Piccinelli M, Barale F, de Ferrari GM: QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005, 4: 1-10.1186/1744-859X-4-1.PubMedCentralCrossRefPubMed
28.
go back to reference Al-Khatib SM, Allen LaPointe NM, Kramer JM, Califf RM: What clinicians should know about the QT interval. JAMA. 2003, 289: 2120-2127. 10.1001/jama.289.16.2120.CrossRefPubMed Al-Khatib SM, Allen LaPointe NM, Kramer JM, Califf RM: What clinicians should know about the QT interval. JAMA. 2003, 289: 2120-2127. 10.1001/jama.289.16.2120.CrossRefPubMed
29.
go back to reference Rijcken CAW, Monster TBM, Brouwers JRBJ, de Jong-van den Berg LTW: Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug dosed?. J Clin Psychopharmacol. 2003, 23: 657-659. 10.1097/01.jcp.0000096247.29231.3a.CrossRefPubMed Rijcken CAW, Monster TBM, Brouwers JRBJ, de Jong-van den Berg LTW: Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug dosed?. J Clin Psychopharmacol. 2003, 23: 657-659. 10.1097/01.jcp.0000096247.29231.3a.CrossRefPubMed
30.
go back to reference Haverkamp W, Breithardt G: Drug-induced sudden cardiac death. Eur Heart J. 2005, 26: 1808-1809. 10.1093/eurheartj/ehi401.CrossRefPubMed Haverkamp W, Breithardt G: Drug-induced sudden cardiac death. Eur Heart J. 2005, 26: 1808-1809. 10.1093/eurheartj/ehi401.CrossRefPubMed
31.
go back to reference Shah SU, Iqbal Z, White A, White S: Heart and mind: psychotropic and cardiovascular therapeutics. Postgrad Med J. 2005, 81: 33-40. 10.1136/pgmj.2003.015230.PubMedCentralCrossRefPubMed Shah SU, Iqbal Z, White A, White S: Heart and mind: psychotropic and cardiovascular therapeutics. Postgrad Med J. 2005, 81: 33-40. 10.1136/pgmj.2003.015230.PubMedCentralCrossRefPubMed
Metadata
Title
QTc and psychopharmacs: are there any differences between monotherapy and polytherapy
Authors
Jadranka Čulav Sumić
Vesna Barić
Petar Bilić
Miroslav Herceg
Mirna Sisek-Šprem
Vlado Jukić
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2007
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/1744-859X-6-13

Other articles of this Issue 1/2007

Annals of General Psychiatry 1/2007 Go to the issue